2. Informed Consent : Must be obtained prior to undergoing any study specific procedures. May be collected more than 28 days prior to study entry. As part of the consenting process, participants will be informed of the potential occurrence of immune related adverse events and will be provided with a Patient Information Card. 3. Tumor History: Will be collected within 28 days prior to study entry. Includes details of primary diagnosis and treatment history. CCI C CI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 18Protocol Activity Screen 1 (£28 days)Treatment Period Post Treatment Cycle 1 Cycle 2 End of Treatment 33Follow- Up (Months after EOT visit)Survival Follow-up35 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 134Month 2 Month 4 Month 6 Post 6-Month Follow-up Cycle Day Day 1Da y 29Day 57Da y 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *±1 ±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 7. Medical History : Includes history of disease process other than NSCLC and TNBC (active or resolved), smoking history, and significant concurre nt illness.